Verified discoveries, trials, and approvals for this cancer type. Every story separates evidence strength, regulatory status, and guideline position.
In the single-arm, phase 2 FIREFLY-1 trial, tovorafenib produced an objective response (tumor shrinkage or resolution) in about 67% of children and young adults with relapsed or refractory, BRAF-altered pediatric…
Primary source cited
Last reviewed
Eflornithine (Iwilfin), an oral drug that blocks an enzyme cancer cells use to make polyamines needed for growth, is the first FDA-approved therapy specifically intended to reduce relapse risk in…
Primary source cited
Last reviewed
In the single-arm, phase 2 FIREFLY-1 trial, tovorafenib produced an objective response (tumor shrinkage or resolution) in about 67% of children and young adults with relapsed or refractory, BRAF-altered pediatric…
Primary source cited
Last reviewed
Eflornithine (Iwilfin), an oral drug that blocks an enzyme cancer cells use to make polyamines needed for growth, is the first FDA-approved therapy specifically intended to reduce relapse risk in…
Primary source cited
Last reviewed
Regulatory approval is separate from evidence certainty and from guideline position. Approval applies only to the exact indication stated in each jurisdiction record.
FIREFLY-1 trial primary results: tovorafenib in relapsed/refractory pediatric low-grade glioma (Nature Medicine). DOI 10.1038/s41591-023-02668-y, PMID 37978284.
Applies to the exact indication stated.
US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy (Journal of Clinical Oncology). DOI 10.1200/JCO.24.00546, PMID 38917371.
Applies to the exact indication stated.
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.